Merrimack Pharma (MACK) Tops Q1 EPS by 5c

Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($0.33), $0.05 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $21.3 million versus the consensus estimate of $24.16 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38